Literature DB >> 4859983

Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin.

H R Casdorph.   

Abstract

The results of administration of cholestyramine to 19 patients for periods of two to 21 months are reported. All patients consistently taking the drug obtained a significant reduction in the serum cholesterol. The average reduction was 26 per cent and the range was from 16 to 52 per cent. Cholestyramine acts as a bile acid sequestering resin, causing an increased loss of bile salts (cholates) in the stool. The drug acts by increasing the normal excretory pathway for cholesterol.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4859983      PMCID: PMC1502666     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  3 in total

1.  CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES.

Authors:  S A HASHIM; T B VANITALLIE
Journal:  JAMA       Date:  1965-04-26       Impact factor: 56.272

2.  Plasma cholesterol lowering action of bile acid binding polymers in experimental animals.

Authors:  D M TENNENT; H SIEGEL; M E ZANETTI; G W KURON; W H OTT; F J WOLF
Journal:  J Lipid Res       Date:  1960-10       Impact factor: 5.922

3.  The disposition of orally administered cholestyraminec14.

Authors:  D G Gallo; A L Sheffner
Journal:  Proc Soc Exp Biol Med       Date:  1965-10
  3 in total
  1 in total

Review 1.  Role of colesevelam in combination lipid-lowering therapy.

Authors:  Michael R Jones; Oliseyenum M Nwose
Journal:  Am J Cardiovasc Drugs       Date:  2013-10       Impact factor: 3.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.